What's happening
This bill expands optometrists' authority to use and prescribe topical pharmaceutical agents for the eye and surrounding tissues.
Why it matters
Expands the types of eye conditions optometrists can treat. by letting them use and prescribe any FDA-approved topical pharmaceutical agents for both the eye and its surrounding structures (adnexa), not just a limited list of drugs.
Removes the strict list of allowable medications,. giving optometrists more flexibility and autonomy to choose among all FDA-approved topical medications, which could improve access to newer or more effective treatments as they become available.
May speed up patient care and reduce referrals,. since optometrists won’t be limited by older, narrower drug lists and can manage a wider range of conditions directly, potentially reducing the need for patients to see ophthalmologists for common eye issues.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Expand Eye Medication Use
Plain English, a few words. Used as the page title.
Sponsors
No co-sponsors yet.
History
- Referred to higher education
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Expand Use of Eye Medications
In Assembly Committee · Higher Education · Sponsor Amy Paulin
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
9726
IN SENATE
May 23, 2024
Introduced by Sen. LIU -- read twice and ordered printed, and when printed to be committed to the Committee on Higher Education
AN ACT to amend the education law, in relation to the use of topical pharmaceutical agents
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Paragraphs (d), (e) and (f) of subdivision 1 of section 7101-a of the education law, paragraph (d) as added by chapter 517 of the laws of 1995 and paragraphs (e) and (f) as amended by chapter 506 of the laws of 2021, are amended to read as follows:
(d) Diagnostic pharmaceuticals. Diagnostic pharmaceuticals shall mean those drugs which shall be limited to topical applications [to the surface of the eye] for the purpose of diagnostic examination of the eye [and shall be limited to:
(i) Anesthetic agents;
(ii) Mydriatics;
(iii) Cycloplegics;
(iv) Miotics;
(v) Disclosing agents and other substances used in conjunction with these drugs as part of a diagnostic procedure] and adnexa.
(e) Topical therapeutic pharmaceutical agents. Topical therapeutic pharmaceutical agents shall mean those drugs which shall be limited to topical application [to the surface of the eye] for therapeutic purposes [and shall be limited to:
(i) antibiotic/antimicrobials;
(ii) decongestants/anti-allergenics;
(iii) non-steroidal anti-inflammatory agents;
(iv) steroidal anti-inflammatory agents;
(v) antiviral agents;
(vi) hyperosmotic/hypertonic agents;
(vii) cycloplegics;
(viii) artificial tears and lubricants; and
(ix) immunosuppressive agents] of the eye and adnexa.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD14942-02-4
(f) Therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension. Therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension shall mean those drugs which shall be limited to topical application [to the surface] for therapeutic purposes of the eye and [shall be limited to:
(i) beta blockers;
(ii) alpha agonists;
(iii) direct acting cholinergic agents;
(iv) prostaglandin analogs; and
(v) carbonic anhydrase inhibitors] adnexa.
§ 2. Paragraph (e) of subdivision 4 of section 7101-a of the education law, as added by chapter 517 of the laws of 1995 and as relettered by chapter 506 of the laws of 2021, is amended to read as follows:
(e) The provisions of paragraphs (a) and (b) of this subdivision shall not apply to (i) graduates of an appropriate program approved by the department who have successfully passed the examination on the use of diagnostic and therapeutic [drugs] agents and who graduated subsequent to January first, nineteen hundred ninety-three; or (ii) optometrists who have been certified for at least five years to use [phase one] topical therapeutic agents and [phase two drugs] therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension in another jurisdiction, have demonstrated such use in independently managed patients, and have been licensed in accordance with section seventy-one hundred four of this chapter. Provided, however, no optometrist exempt under this paragraph shall be permitted to use [phase one] topical therapeutic pharmaceutical agents or [phase two] therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension prior to the general authorization provided to optometrists licensed in this state.
§ 3. The opening paragraph of paragraph (b) and paragraph (c) of subdivision 10 of section 7101-a of the education law, as amended by chapter 506 of the laws of 2021, are amended to read as follows:
Those optometrists having been certified for topical therapeutic pharmaceutical agents shall be authorized to use and prescribe all topical therapeutic pharmaceutical agents [specified in paragraph (e) of subdivision one of this section], which are FDA approved and commercially available for topical use.
(c) Those optometrists having been certified for therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension shall be authorized to use and prescribe therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension [specified in paragraph (f) of subdivision one of this section], which are FDA approved and commercially available.
§ 4. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the education law, in relation to the use of topical pharmaceutical agents
Purpose
The purpose of this bill is to allow optometrists to use any topical pharmaceutical agents related to the treatment of the eye and adnexa.
Summary of provisions
Section 1: Amends subdivision 1 of § 7101-a of the education law to remove the list of topical pharmaceutical agents and allow optometrists to use any topical agent for the treatment of patients' eye conditions, provided it is the standard of care for such treatment, it is within the scope of practice for optometry, such optometrist is qualified pursuant to the Education Law, and the agent is FDA approved and commercially available for topical use. It would also clarify that topical pharmaceu- ticals are for treatment related to the adnexa, which includes the eyel- ids, the conjunctival sac, the lacrimal drainage system, the lacrimal gland, and would create consistency given that adnexa is codified else- where in this subdivision (e.g., Educ. Law § 7101- a(1)(g)).
Section 2: Amends subdivision 4 of § 7101-a of the education law to correct terminology so it is consistent with existing terms in the stat- ute including that topical therapeutic agents are no longer referred to as "phase one" drugs and therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension are no longer referred to as "phase two" drugs, pursuant to amendments enacted in 2021.
Section 3: Amends subdivision 4 of § 7101-a of the education law to remove a cross-reference to the list of topical drugs that will no long- er be specified with enactment of this bill into law.
Section 4: Provides that this act shall take effect immediately.
Justification
Doctors of Optometry were authorized to treat their patients using diag- nostic pharmaceutical topical agents in 1983 and topical therapeutic pharmaceutical agents in 1995. The statute has listed the specific topical agents that could be used since those years. However, new agents have been developed for the treatment of the eye and adnexa since and optometrists have not been able to immediately use them. This harms the treatment of patients since the topical agent may be the standard of care for a particular eye condition and yet the optometrist cannot use it unless potentially seeking an amendment to the statute to add it to the list.
In the more than 50 years and nearly 40 years, respectively, since the statutory authorization for optometrists to use topical pharmaceutical agents, optometrists have been qualified and have demonstrated an exper- tise in using such agents to the benefit of their patients and improved healthcare delivery. There are currently over 3,000 optometrists licensed in New York State who provide primary eye care throughout the state, including in underserved urban and rural areas. Given the many challenges which limit access to healthcare for many New Yorkers, it is vital that optometrists be provided the authority to use the topical agents that will allow them to treat their patients' eye conditions without delay and without pursuing time-consuming legislative and regu- latory processes.
Fiscal impact on the state
None.
Legislative history
New bill.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.